Table 1 Baseline characteristics in the study cohorts
Characteristic | Procalcitonin and survival study (PASS) (n = 936) | Transfusion requirements in septic shock (TRISS) trial (n = 856) | Cleveland clinics medical ICU cohort (n = 10,550) | |||
|---|---|---|---|---|---|---|
Median age—years (IQR) | 67 (58–76) | 66 (58–74) | 64 (54–74) | |||
Male sex—no. (%) | 515 (55) | 390 (46) | 5502 (52) | |||
Median BMI—index (IQR) | 25 (22–28) | 28 (23–34) | ||||
Median weight—kg (IQR) | 75 (63–87) | 75 (64–87) | 80 (66–98) | |||
Blood type—no. (%) | ||||||
A | 420 (45) | 368 (43) | 3942 (37) | |||
B | 102 (11) | 95 (11) | 1523 (14) | |||
AB | 39 (4) | 31 (4) | 433 ( 4) | |||
O | 375 (40) | 362 (42) | 4652 (44) | |||
Diabetes—no. (%) | 138 (15) | – | 4552 (43) | |||
Hypertension—no. (%) | 168 (18) | – | 7109 (67) | |||
Charlson Score ≥ 2—no. (%) | 333 (36) | – | 8828 (84) | |||
Median SOFA—score (IQR) | 7 (4–9) | 10 (8–12) | 6 (4–9) | |||
Mechanical ventilation—no. (%) | 629 (67) | 611 (71) | 1356 (13) | |||
Median creatinine µmol/L (IQR) | 127 (80–215) | 131 (79–203) | 129 (80–241) | |||
Renal replacement therapy—no. (%) | 152 (16) | 103 (12) | 148 ( 1) | |||
Median urinary output—mL/kg/h (IQR) | 1.1 (0.5–1.7) | – | ||||
Median MAP—mmHg (IQR) | 71 (61–84) | 58 (52–63) | 63 (54–72) | |||
Vasopressor treatment—no. (%) | 433 (46) | 765 (89) | 2330 (22) | |||
Inotropic treatment—no. (%) | 201 (22) | – | – | |||
Septic shock—no. (%) | 603 (64) | 856 (100) | 4714 (55) | |||
Median platelet count— × 106/L (IQR) | 234 (148–333) | – | 165 (93–244) | |||
Median WBC—× 106/L (IQR) | 13 (9–19) | – | – | |||
Median bilirubin—µmol/L (IQR) | 10 (5–18) | – | 12 (7–27) | |||